[1] O′Toole SA, Beith JM, Millar EK, et al. Therapeutic targets in triple negative breast cancer[J]. J Clin Pathol, 2013, 66(6): 530-542. DOI: 10.1136/jclinpath-2012-201361.
[2] de Ruijter TC, Veeck J, de Hoon JP, et al. Characteristics of triplenegative breast cancer[J]. J Cancer Res Clin Oncol, 2011, 137(2): 183192. DOI: 10.1007/s00432-010-0957x.
[3] Verma S, Provencher L, Dent R. Emerging trends in the treatment of triplenegative breast cancer in Canada: a survey[J]. Curr Oncol, 2011, 18(4): 180-190.
[4] Brewster AM, ChavezMacGregor M, Brown P. Epidemiology, biology, and treatment of triplenegative breast cancer in women of African ancestry[J]. Lancet Oncol, 2014, 15(13): e625-e634. DOI: 10.1016/S1470-2045(14)70364X.
[5] Zhang G, Xie W, Liu Z, et al. Prognostic function of Ki67 for pathological complete response rate of neoadjuvant chemotherapy in triplenegative breast cancer[J]. Tumori, 2014, 100(2): 136-142. DOI: 10.1700/1491.16395.
[6] Mantovani A. Cancer: inflaming metastasis[J]. Nature, 2009, 457(7225): 36-37. DOI: 10.1038/457036b.
[7] Haddad CR, Guo L, Clarke S, et al. Neutrophiltolymphocyte ratio in head and neck cancer[J]. J Med Imaging Radiat Oncol, 2015, 59(4): 514-519. DOI: 10.1111/17549485.12305.
[8] Kang MH, Go SI, Song HN, et al. The prognostic impact of the neutrophiltolymphocyte ratio in patients with smallcell lung cancer[J]. Br J Cancer, 2014, 111(3): 452460. DOI: 10.1038/bjc.2014.317.
[9] Feng JF, Huang Y, Liu JS. Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma[J]. Onco Targets Ther, 2013, 6: 16051612. DOI: 10.2147/OTT.S52501.
[10] Xue P, Kanai M, Mori Y, et al. Neutrophiltolymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients[J]. Cancer Med, 2014, 3(2): 406-415. DOI: 10.1002/cam4.204.
[11] Rachidi S, Wallace K, Wrangle JM, et al. Neutrophiltolymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma[J]. Head Neck, 2016, 38 Suppl 1: E1068-E1074. DOI: 10.1002/hed.24159.
[12] Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumorinfiltrating lymphocytes in triplenegative breast cancers from two phase Ⅲ randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199[J]. J Clin Oncol, 2014, 32(27): 2959-2966. DOI: 10.1200/JCO.2013.55.0491.
[13] HernandezAya LF, ChavezMacgregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of patients with triplenegative breast cancer[J]. J Clin Oncol, 2011, 29(19): 2628-2634. DOI: 10.1200/JCO.2010.32.1877.
[14] Foulkes WD, Metcalfe K, Hanna W, et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1related breast carcinoma[J]. Cancer, 2003, 98(8): 15691577. DOI: 10.1002/cncr.11688.
[15] Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients?[J]. Curr Opin Pharmacol, 2009, 9(4): 351-369. DOI: 10.1016/j.coph.2009.06.020.
[16] Curry JM, Sprandio J, Cognetti D, et al. Tumor microenvironment in head and neck squamous cell carcinoma[J]. Semin Oncol, 2014, 41(2): 217-234. DOI: 10.1053/j.seminoncol.2014.03.003. |